Beijing has released a number of policies to improve the environment and transition to clean, energy-efficient industry, resulting in the shuttering of high-pollutant operations.
China Market Intelligence
Eighty-nine percent of US-China Business Council (USCBC) member companies view rising costs as a top concern in the China market, according to USCBC’s 2017 Member Survey.
China’s National Development and Reform Commission (NDRC) recently announced its 2018 priorities for pricing investigations under the anti-monopoly law (AML), listing key industries in which it says price-fixing tactics
Despite indications that US companies expect growth in revenue and profitability next year in China, concern about possible trade actions was evident in polling USCBC members who attended the Shanghai China Operations Conference on November 30.
Chinese regulations on tendering and bidding practices published by the Ministry of Finance (MOF) in July are a promising sign for US pharmaceutical and medical device manufacture
The US-China Business Council (USCBC) recently submitted comments to the China Food and Drug Administration (CFDA) on the
Intellectual property (IP) theft and forced technology transfer are serious issues that need to be addressed in China, said Senior Vice President Erin Ennis in testimony about
Recently announced provincial reimbursement drug lists (PRDLs) provide possible new opportunities for US pharmaceutical companies seeking to expand market reach for their drugs in China.
Changes stemming from the implementation of China’s Food Safety Law threaten to block imports of a wide range of food products from countries unable to provide the necessary certificates.